Analyst Price Targets — GSK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 30, 2025 11:27 am | Wan Nurhayati | CFRA | $53.00 | $46.67 | StreetInsider | CFRA Upgrades GlaxoSmithKline (GSK) to Buy |
| April 15, 2025 4:37 pm | Peter Verdult | BNP Paribas | $35.25 | $35.68 | TheFly | GSK initiated with a Neutral at BNP Paribas Exane |
| July 2, 2024 6:21 am | Peter Welford | Jefferies | $53.00 | $38.38 | TheFly | GSK price target raised to $53 from $52.50 at Jefferies |
| April 11, 2024 7:48 am | Vamil Divan | Guggenheim | $36.00 | $40.69 | Benzinga | Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields |
| April 11, 2024 7:48 am | Mark Purcell | Morgan Stanley | $85.00 | $40.69 | Benzinga | Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields |
Latest News for GSK
HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfront payment, according to Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng.
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to 205.84p as Cavendish and Panmure Liberum reiterated their respective 'buy' ratings, arguing that the market continues to overlook…
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. The shares were up 30.5p from Wednesday's 179.5p close following news that GSK will receive exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop…
GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for solid tumours, the Chinese drugmaker said on Thursday.
GSK to advance its mRNA flu vaccine into phase III after phase II study has shown stronger immune responses and good tolerability.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for GSK.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.